Share on StockTwits

Investment analysts at Oppenheimer cut their price target on shares of NPS Pharmaceuticals (NASDAQ:NPSP) from $44.00 to $40.00 in a note issued to investors on Friday, Analyst Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target indicates a potential upside of 45.35% from the stock’s previous close.

NPSP has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of NPS Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Thursday, May 1st. They now have a $32.00 price target on the stock. Separately, analysts at Canaccord Genuity initiated coverage on shares of NPS Pharmaceuticals in a research note on Wednesday, April 16th. They set a “buy” rating and a $42.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of NPS Pharmaceuticals in a research note on Monday, March 24th. They set a “buy” rating and a $45.00 price target on the stock. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. NPS Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $39.27.

NPS Pharmaceuticals (NASDAQ:NPSP) traded up 13.86% during mid-day trading on Friday, hitting $27.52. The stock had a trading volume of 4,698,347 shares. NPS Pharmaceuticals has a one year low of $13.59 and a one year high of $39.68. The stock has a 50-day moving average of $26.76 and a 200-day moving average of $29.90. The company’s market cap is $2.829 billion.

NPS Pharmaceuticals (NASDAQ:NPSP) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. The company had revenue of $44.04 million for the quarter, compared to the consensus estimate of $48.30 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 73.2% on a year-over-year basis. On average, analysts predict that NPS Pharmaceuticals will post $0.18 earnings per share for the current fiscal year.

NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.